Cath Mummery is a consultant neurologist with a special interest in cognitive disorders, working at the National Hospital for Neurology and Neurosurgery. She trained at Kings College Hospital and the National Hospital for Neurology and Neurosurgery, gaining a PhD in cognitive neurology at UCL via an MRC fellowship. She leads the clinical cognitive disorders service at NHNN, a national service with particular interest in genetic and atypical dementias and is clinical director in neurology at NHNN. She has an academic role as Head of Novel Therapeutics at the Dementia Research Centre, UCL and has been senior investigator on over 20 drug trials of disease modifying agents, focussing on early phase and secondary prevention trials in sporadic and genetic forms of dementia. She is UK chief investigator for pivotal studies such as DIAN-TU, trialling immunotherapy in presymptomatic individuals at risk of genetic AD, and a first-in-human phase I antisense oligonucleotide study, reducing tau accumulation in AD. She is Deputy Director for the Leonard Wolfson Experimental Neurology Centre at NHNN, a unit dedicated to early phase trials in neurodegeneration. She has a national role as Chair of ABN Services Committee and works to ensure the neurology voice is heard about clinical matters. She also has an active role in the Royal College of Physicians as neuroscience representative. She is passionate about improving access to research for individuals with AD and sits on the steering committee for the Alzheimer’s Research UK Dementia Access Taskforce, which aims to enhance early recognition of disease, improve access to trials and address challenges new treatments in dementia will bring to the clinic.